Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX: